Literature DB >> 12222680

Methylation of the RASSF1A gene in human cancers.

Gerd P Pfeifer1, Jung-Hoon Yoon, Limin Liu, Stella Tommasi, Sharon P Wilczynski, Reinhard Dammann.   

Abstract

Loss of genetic material from chromosome 3p21.3 is one of the most common and earliest events in the pathogenesis of lung cancer and many other solid tumors. The chromosomal area 3p21.3 is thought to harbor at least one important tumor suppressor gene, which, despite many years of investigation, has remained elusive. In our previous studies, we have identified and cloned a gene from the common homozygous deletion area at 3p21.3. The gene, named RASSF1A (Ras ASSociation domain Family 1A), has homology to a mammalian Ras effector. The RASSF1A gene is epigenetically inactivated in a large percentage of human lung cancers, in particular small cell carcinomas. A high frequency of methylation of RASSF1A is found also in breast cancers, renal cell carcinomas, ovarian, gastric and bladder cancers, and in neuroblastomas. The RASSF1A gene is a candidate for a tumor suppressor gene in 3p21.3.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12222680     DOI: 10.1515/BC.2002.097

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  41 in total

1.  RASSF1A promoter methylation and Kras2 mutations in non small cell lung cancer.

Authors:  Jie Li; Zhongqiu Zhang; Zunyan Dai; Anthony P Popkie; Christoph Plass; Carl Morrison; Yian Wang; Ming You
Journal:  Neoplasia       Date:  2003 Jul-Aug       Impact factor: 5.715

2.  Epigenetic regulation of the tumor suppressor gene TCF21 on 6q23-q24 in lung and head and neck cancer.

Authors:  Laura T Smith; Mauting Lin; Romulo M Brena; James C Lang; David E Schuller; Gregory A Otterson; Carl D Morrison; Dominic J Smiraglia; Christoph Plass
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-13       Impact factor: 11.205

Review 3.  DNA methylation profiles in cancer diagnosis and therapeutics.

Authors:  Yunbao Pan; Guohong Liu; Fuling Zhou; Bojin Su; Yirong Li
Journal:  Clin Exp Med       Date:  2017-07-27       Impact factor: 3.984

4.  Deletion of XPC leads to lung tumors in mice and is associated with early events in human lung carcinogenesis.

Authors:  M Christine Hollander; Robyn T Philburn; Andrew D Patterson; Susana Velasco-Miguel; Errol C Friedberg; R Ilona Linnoila; Albert J Fornace
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-02       Impact factor: 11.205

5.  The RASSF1A isoform of RASSF1 promotes microtubule stability and suppresses tumorigenesis.

Authors:  L van der Weyden; K K Tachibana; M A Gonzalez; D J Adams; B L Ng; R Petty; A R Venkitaraman; M J Arends; A Bradley
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

6.  Epigenetic reactivation of RASSF1A by phenethyl isothiocyanate (PEITC) and promotion of apoptosis in LNCaP cells.

Authors:  Sarandeep S S Boyanapalli; Wenji Li; Francisco Fuentes; Yue Guo; Christina N Ramirez; Ximena-Parades Gonzalez; Douglas Pung; Ah-Ng Tony Kong
Journal:  Pharmacol Res       Date:  2016-11-03       Impact factor: 7.658

7.  Methylation of RASSF1A gene promoter is regulated by p53 and DAXX.

Authors:  Hailong Zhang; Jing He; Jiansha Li; Dan Tian; Lubing Gu; Muxiang Zhou
Journal:  FASEB J       Date:  2012-10-04       Impact factor: 5.191

8.  Frequent and distinct aberrations of DNA methylation patterns in fibrolamellar carcinoma of the liver.

Authors:  Wolfgang Tränkenschuh; Florian Puls; Matthias Christgen; Cord Albat; Albert Heim; Jeanette Poczkaj; Peer Fleming; Hans Kreipe; Ulrich Lehmann
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

9.  Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms.

Authors:  Michael G House; James G Herman; Ming Zhou Guo; Craig M Hooker; Richard D Schulick; Keith D Lillemoe; John L Cameron; Ralph H Hruban; Anirban Maitra; Charles J Yeo
Journal:  Ann Surg       Date:  2003-09       Impact factor: 12.969

10.  Novel type of Ras effector interaction established between tumour suppressor NORE1A and Ras switch II.

Authors:  Benjamin Stieglitz; Christine Bee; Daniel Schwarz; Ozkan Yildiz; Anna Moshnikova; Andrei Khokhlatchev; Christian Herrmann
Journal:  EMBO J       Date:  2008-07-03       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.